Summary of Significant Accounting Policies (Tables)

9 Months Ended

Dec. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of disaggregation of revenue

	For the Three Months Ended December 31,				For the Nine Months Ended December 31,
	2018		2017		2018		2017
NDA:
Licensing fees	$	250,000	$	250,000	$	750,000	$	750,000
Total NDA revenue		250,000		250,000		750,000		750,000
ANDA:
Manufacturing fees	$	2,108,487	$	2,083,826	$	4,456,832	$	4,160,949
Licensing fees		335,479		201,628		1,017,881		950,856
Total ANDA revenue		2,443,966		2,285,454		5,474,713		5,111,805
Total revenue	$	2,693,966	$	2,535,454	$	6,224,713	$	5,861,805

Schedule of earnings (loss) per share applicable to common shareholders

	For the Three Months Ended December 31,						For the Nine Months Ended December 31,
	2018			2017			2018			2017
Numerator
Net loss attributable to common shareholders - basic	$	(2,344,318	)	$	(490,181	)	$	(6,615,616	)	$	(843,758	)
Effect of dilutive instrument on net loss		(380,976	)		(605,448	)		(807,347	)		(4,767,884	)
Net loss attributable to common shareholders - diluted	$	(2,725,294	)	$	(1,095,629	)	$	(7,422,963	)	$	(5,611,642	)
Denominator
Weighted average shares of common stock outstanding - basic		819,412,807			788,442,363			811,603,678			796,647,284
Dilutive effect of stock options, warrants and convertible securities		56,074			6,680,001			56,074			6,680,001
Weighted average shares of common stock outstanding - diluted		819,468,881			795,122,364			811,659,752			803,327,285
Net income (loss) per share
Basic	$	(0.00	)	$	(0.00	)	$	(0.01	)	$	(0.00	)
Diluted	$	(0.00	)	$	(0.00	)	$	(0.01	)	$	(0.01	)

Schedule of liabilities measured at fair value on a recurring basis

	Amount at		Fair Value Measurement Using
	Fair Value		Level 1		Level 2		Level 3
December 31, 2018
Liabilities
Derivative financial instruments - warrants	$	1,860,524	$	-	$	-	$	1,860,524
March 31, 2018
Liabilities
Derivative financial instruments - warrants	$	2,667,871	$	-	$	-	$	2,667,871